Profile: Ligand Pharmaceuticals, Inc. is a specialty pharmaceutical company that discovers, develops & distributes innovative small molecule drugs to address critical, unmet medical needs. We have forged several joint programs aimed at developing compounds generated by our proprietary intracellular (IR) technology for large market indications. Our product pipeline comprises of dual acting receptor agonist (DARA), selective androgen receptor modulators (SARM), erythropoiein (EPO), androgen-independent prostate cancer (AiPC) and selective glucocorticoid receptor modulators (SGRM). Our tissue-selective SARMs is a novel class of non-steroidal, orally active molecules that selectively modulate the activity of the androgen receptor in different tissues, providing a wide range of opportunities for the treatment of many diseases & disorders such as frailty, cachexia, osteoporosis, sexual dysfunction & hypogonadism. We are researching SGRMs for potentially favorable effects in inflammation, cancer, and other indications.